Skip to main content
Article thumbnail
Location of Repository

Iodinated contrast media and cerebral hemorrhage after intravenous thrombolysis

By N.J.J. MacDougall, F. McVerry, S. Baird, T. Baird, E. Teasdale and K.W. Muir

Abstract

<p>Background and Purpose: Iodinated contrast is increasingly used in CT perfusion or angiographic examinations in acute stroke. Increased risk of intracranial hemorrhage (ICH) complicating microcatheter contrast injections has recently been reported in the second Interventional Management of Stroke (IMS 2) trial with contrast toxicity potentially contributory.</p>\ud \ud <p>Methods: We reviewed clinical and radiological data on all patients treated with intravenous alteplase at a single center between May 2003 and November 2008.</p>\ud \ud <p>Results: Of 312 patients treated with intravenous alteplase, 69 (22.1%) received intravenous iodinated contrast in volumes between 50 and 150 mL. Incidence of symptomatic ICH defined as per European Cooperative Acute Stroke Study 2 was 16 of 312 (5.1%; 95% CI, 2.7% to 7.6%); among patients not given contrast, it was 12 of 243 (4.9%; 2.2% to 7.7%) compared with 4 of 69 (5.8%; 0.3% to 11.3%) in those given contrast. Incidence of symptomatic ICH defined as per Safe Implementation of Thrombolysis in Stroke-MOnitoring Study (SITS-MOST) criteria was 12 of 312 (3.9%; 1.7% to 6%), 9 of 243 (3.7%; 1.3% to 6%) among those not given contrast, and 3 of 69 (4.4%; 95% CI, -0.5% to 9.2%) among those given contrast. Patients with symptomatic ICH were older, had higher pretreatment National Institutes of Health Stroke Scale, and blood glucose than those without symptomatic ICH. In logistic regression analysis, pretreatment blood glucose was the only significant predictor of symptomatic ICH by either definition (OR, 1.23; 95% CI, 1.03 to 1.48 per mmol/L increment; P=0.024). Contrast administration or dose was not associated with symptomatic ICH.</p>\ud \ud <p>Conclusions: Intravenous iodinated contrast in doses typically required for CT angiography and perfusion imaging was not associated with symptomatic intracranial hemorrhage in patients treated with alteplase.</p&gt

Topics: RC0321
Publisher: American Heart Association
Year: 2011
OAI identifier: oai:eprints.gla.ac.uk:57605
Provided by: Enlighten

Suggested articles

Citations

  1. A comparison of blood–brain barrier disruption by intracarotid iohexol and iodixanol in the rabbit.
  2. (1998). Are iodinated contrast agents detrimental in acute cerebral ischemia? An experimental study in rats. Radiology.
  3. (2011). Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: results from the Safe Implementation of Treatments
  4. (2001). Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. Neurology.
  5. Do iodinated contrast agents impair fibrinolysis in acute stroke? A systematic review.
  6. Dynamic of hyperglycemia as a predictor of stroke outcome in the ECASS-II trial.
  7. Intra-arterial iodinated radiographic contrast material injection administration in a rat middle cerebral artery occlusion and reperfusion model: possible effects on intracerebral hemorrhage.
  8. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study
  9. Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study.
  10. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the multicenter rtPA stroke survey.
  11. Microcatheter contrast injections during intra-arterial thrombolysis increase intracranial hemorrhage risk.
  12. Microcatheter contrast injections during intra-arterial thrombolysis may increase intracranial hemorrhage risk.
  13. (2006). MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurol.
  14. MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: an analysis of 1210 patients.
  15. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials. Safe Implementation of Thrombolysis in StrokeMonitoring Study (SITS-MOST).
  16. (1998). Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase
  17. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European–Australasian Acute Stroke Study (ECASS II).
  18. Safety of performing CT angiography in stroke patients treated with intravenous thrombolysis.
  19. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke.
  20. Thrombolysis with alteplase 3–4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study.
  21. Thrombolytic therapy for acute stroke in the united kingdom: experience from the Safe Implementation of Thrombolysis
  22. Trial Investigators. The Interventional Management of Stroke (IMS) II study.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.